Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
White Paper
Finding the best entry strategies into new markets
Exploring the four key routes to market
Jan 31, 2019
  • Library
  • Finding the best entry strategies into new markets
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

For biopharma companies, extending focus to new markets presents a great potential but navigating the entry – be it into emerging or well-established markets – can be complicated, costly, and time-consuming. This paper outlines the obstacles biopharma companies can face when entering new markets, the benefits and risks of different market access strategies, and how to choose an approach that delivers long-term value to their business.

As the biopharma and healthcare industries become more global, markets outside companies' primary existing focus are becoming more attractive. For some companies, this may mean exploring beyond their established markets of the U.S., Japan, and EU5 into emerging markets such as Turkey, the BRIC (Brazil, Russia, India, China) countries, or the Middle East, Africa, and Latin America. For domestic companies that are established in their own market, such as those with a well-known brand in countries like Japan, China, or India, this could mean staking a claim in Europe or the U.S.


BUILDING A BASE IN THE EMERGING MARKETS

The share of biopharma spend in the emerging markets has grown from 13% in 2007 to 24% in 2017, an average rate of increase of 12.8%. While the rate of growth is slowing, it's still expected to continue to grow by 6-9% to $345- 375 billion by 2022. The growth in the emerging markets is driven by aging populations, improved prosperity, and government initiatives to bolster access to better healthcare. The need for more robust pharmaceutical treatment options in many of the emerging countries remains substantial. Populations in these countries suffer from a myriad of chronic health issues, including diabetes, cancer, heart disease, and others. China and India have high populations of people with diabetes with 121 million and 74 million, respectively. The highest upsurge is expected to be in African, Middle Eastern, Northern African, and South-East Asian regions over the next three decades. The leading cause of death in Russia is cardiovascular disease, accounting for over half of deaths in this region. In Brazil, the top three causes of death are ischemic heart disease, stroke, and lower respiratory tract infections.

The growth of developed markets is slowing. Branded drug net spending growth has flattened over the past five years. This means that emerging markets aren’t just going to be a 'nice to have' side business. In the coming years they are likely to represent larger proportions of sales volumes, making them vital to long-term profitability. While these countries still have relatively low price thresholds, the large volume of need makes them important strategic destinations for biopharma companies, but only if they can develop targeted market plans that address the unique needs of local consumers, physicians, regulators, and payers.


GROWING OUT OF A DOMESTIC BASE

It's not just about the emerging markets though. For a domestic company, for example in India or China, extending into other markets would allow them to access the opportunities in the U.S. or Europe. As an example of an opportunity, specialty pharmaceuticals are growing in the developing world. The predicted 2018 specialty spend in the developed world has grown from $172 billion in 2013, and now makes up 41% of developed market spending.

Bringing a drug to market in a new destination country can be fraught with risk. Evolving regulations, lack of an inhouse sales network on the ground, unfamiliar marketplace mechanics, and uncertainty about local laws and IP protection are just a few of the challenges that biopharma companies face when they try to break into an unfamiliar market. It can be difficult for larger biopharma companies that may have the time and resources to establish the necessary infrastructure, relationships, and feet on the ground to establish its brand in these destinations. For small and mid-sized companies, choosing the right strategy is vital for success. Companies, both large and small, are looking for smarter ways to enter new regions.


DOWNLOAD TO LEARN MORE

Related solutions

Contact Us